{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:25Z","timestamp":1791041845662,"version":"4.1.0"},"reference-count":23,"publisher":"Japanese Society of Toxicology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2131\/jts.43.369","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T18:34:40Z","timestamp":1528137280000},"page":"369-375","source":"Crossref","is-referenced-by-count":12,"title":["Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA"],"prefix":"10.2131","volume":"43","author":[{"given":"Norie","family":"Murayama","sequence":"first","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suemizu","sequence":"additional","affiliation":[{"name":"Central Institute for Experimental Animals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Uehara","sequence":"additional","affiliation":[{"name":"Central Institute for Experimental Animals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kusama","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Peter","family":"Guengerich","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Chanan-Khan, A.A., Lonial, S., Weber, D., Borrello, I., Fo\u00e0, R., Hellmann, A., Dimopoulos, M., Swern, A.S. and Knight, R. (2012): Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients \u226565 years old with relapsed or refractory multiple myeloma. Int. J. Hematol., <b>96<\/b>, 254-262.","DOI":"10.1007\/s12185-012-1125-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chen, N., Kasserra, C., Reyes, J., Liu, L. and Lau, H. (2012a): Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother. Pharmacol., <b>70<\/b>, 717-725.","DOI":"10.1007\/s00280-012-1966-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J.B., Knight, R. and Laskin, O.L. (2007): Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol., <b>47<\/b>, 1466-1475.","DOI":"10.1177\/0091270007309563"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chen, N., Wen, L., Lau, H., Surapaneni, S. and Kumar, G. (2012b): Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother. Pharmacol., <b>69<\/b>, 789-797.","DOI":"10.1007\/s00280-011-1760-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chen, N., Zhou, S. and Palmisano, M. (2017): Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin. Pharmacokinet., <b>56<\/b>, 139-152.","DOI":"10.1007\/s40262-016-0432-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Chowdhury, G., Shibata, N., Yamazaki, H. and Guengerich, F.P. (2014): Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem. Res. Toxicol., <b>27<\/b>, 147-156.","DOI":"10.1021\/tx4004215"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hasegawa, M., Kawai, K., Mitsui, T., Taniguchi, K., Monnai, M., Wakui, M., Ito, M., Suematsu, M., Peltz, G., Nakamura, M. and Suemizu, H. (2011): The reconstituted \u2018humanized liver\u2019 in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun., <b>405<\/b>, 405-410.","DOI":"10.1016\/j.bbrc.2011.01.042"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hirom, P.C., Millburn, P., Smith, R.L. and Williams, R.T. (1972): Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem. J., <b>129<\/b>, 1071-1077.","DOI":"10.1042\/bj1291071"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. and Handa, H. (2010): Identification of a primary target of thalidomide teratogenicity. Science, <b>327<\/b>, 1345-1350.","DOI":"10.1126\/science.1177319"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kim, Y. and Schmidt-Wolf, I.G. (2015): Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther., <b>15<\/b>, 491-497.","DOI":"10.1586\/14737140.2015.1033407"},{"key":"11","first-page":"2326","year":"2012","unstructured":"Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. and Chopra, R. (2012): Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, <b>26<\/b>, 2326-2335.","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Murayama, N., van Beuningen, R., Suemizu, H., Guillouzo, C.G., Shibata, N., Yajima, K., Utoh, M., Shimizu, M., Chesn\u00e9, C., Nakamura, M., Guengerich, F.P., Houtman, R. and Yamazaki, H. (2014): Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem. Res. Toxicol., <b>27<\/b>, 304-308.","DOI":"10.1021\/tx4004374"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Nishiyama, S., Suemizu, H., Shibata, N., Guengerich, F.P. and Yamazaki, H. (2015): Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem. Res. Toxicol., <b>28<\/b>, 2088-2090.","DOI":"10.1021\/acs.chemrestox.5b00381"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Okubo, S., Miyamoto, M., Ito, D., Takami, K. and Ashida, K. (2016): Albumin and apolipoprotein H mRNAs in human plasma as potential clinical biomarkers of liver injury: analyses of plasma liver-specific mRNAs in patients with liver injury. Biomarkers, <b>21<\/b>, 353-362.","DOI":"10.3109\/1354750X.2016.1141987"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Okubo, S., Miyamoto, M., Takami, K., Kanki, M., Ono, A., Nakatsu, N., Yamada, H., Ohno, Y. and Urushidani, T. (2013): Identification of novel liver-specific mRNAs in plasma for biomarkers of drug-induced liver injury and quantitative evaluation in rats treated with various hepatotoxic compounds. Toxicol. Sci., <b>132<\/b>, 21-31.","DOI":"10.1093\/toxsci\/kfs340"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Rozewski, D.M., Herman, S.E., Towns, W.H. 2nd, Mahoney, E., Stefanovski, M.R., Shin, J.D., Yang, X., Gao, Y., Li, X., Jarjoura, D., Byrd, J.C., Johnson, A.J. and Phelps, M.A. (2012): Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J., <b>14<\/b>, 872-882.","DOI":"10.1208\/s12248-012-9401-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Shimizu, M., Suemizu, H., Mitsui, M., Shibata, N., Guengerich, F.P. and Yamazaki, H. (2017): Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica, <b>47<\/b>, 844-848.","DOI":"10.1080\/00498254.2016.1247218"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Tsukada, A., Suemizu, H., Murayama, N., Takano, R., Shimizu, M., Nakamura, M. and Yamazaki, H. (2013): Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in <i>in vivo<\/i> experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol., <b>65<\/b>, 316-324.","DOI":"10.1016\/j.yrtph.2013.01.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. and Knight, R.D.; Multiple Myeloma (009) Study Investigators. (2007): Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med., <b>357<\/b>, 2133-2142.","DOI":"10.1056\/NEJMoa070596"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Yamazaki, H., Suemizu, H., Kazuki, Y., Oofusa, K., Kuribayashi, S., Shimizu, M., Ninomiya, S., Horie, T., Shibata, N. and Guengerich, F.P. (2016a): Assessment of protein binding of 5-hydroxythalidomide bioactivated in humanized mice with human P450 3A-chromosome or hepatocytes by two-dimensional electrophoresis\/accelerator mass spectrometry. Chem. Res. Toxicol., <b>29<\/b>, 1279-1281.","DOI":"10.1021\/acs.chemrestox.6b00210"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Yamazaki, H., Suemizu, H., Mitsui, M., Shimizu, M. and Guengerich, F.P. (2016b): Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem. Res. Toxicol., <b>29<\/b>, 1903-1911.","DOI":"10.1021\/acs.chemrestox.6b00136"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Yamazaki, H., Suemizu, H., Murayama, N., Utoh, M., Shibata, N., Nakamura, M. and Guengerich, F.P. (2013): <i>in vivo<\/i> drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem. Res. Toxicol., <b>26<\/b>, 486-489.","DOI":"10.1021\/tx400008g"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Yamazaki, H., Suemizu, H., Shimizu, M., Igaya, S., Shibata, N., Nakamura, M., Chowdhury, G. and Guengerich, F.P. (2012): <i>in vivo<\/i> formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem. Res. Toxicol., <b>25<\/b>, 274-276.","DOI":"10.1021\/tx300009j"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/43\/6\/43_369\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T22:18:53Z","timestamp":1571437133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/43\/6\/43_369\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.43.369","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}